Iovance Biotherapeutics Inc logo

Iovance Biotherapeutics Inc(IOVA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$6.9
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IOVA

11/20/2026: IOVA (1-star) is currently NOT-A-BUY. Pass it for now.

Iovance Biotherapeutics is a commercial-stage biotechnology company specializing in personalized tumor-infiltrating lymphocyte (TIL) cell therapies for advanced solid tumors. Its primary strength lies in its pioneering market position and FDA approval of Amtagvi for advanced melanoma, supported by dedicated manufacturing infrastructure. The primary investment growth story centers on scaling commercial adoption and expanding label indications into other major solid tumors like lung cancer. Key risks include high operational cash burn, complex autologous manufacturing constraints, and potential reimbursement hurdles. The stock best suits growth-oriented investors willing to accept high volatility, with ongoing developments in treatment center expansion and clinical trial readouts remaining essential metrics to monitor.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers significant top-line expansion potential driven by the commercial rollout and label expansion of its breakthrough cell therapy products.
Momentum investorStrong fit while signal remains positiveStock price movements often react strongly to clinical trial readouts, regulatory updates, and quarterly commercial sales milestones.
Value investorWeak fitThe company currently operates at a net loss and trades on future growth potential rather than traditional valuation multiples or earnings.
Dividend investorWeak fitIovance pays no dividends and retains all capital to fund commercialization and clinical pipeline expansion.
Low-risk investorWeak fitHigh clinical, regulatory, and execution volatility inherent to commercial-stage biotechnology companies exposes investors to substantial downside risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences sharp price swings reacting to regulatory news, clinical data, and commercial execution milestones.
Valuation riskMedium / highValuation is largely dependent on long-term commercial projections for Amtagvi and pipeline success.
Competition risk (oncology and cellular therapy competition)Medium / highThe company faces ongoing competitive pressures from established immunotherapies and emerging next-gen cell therapy developers.
Business qualityMediumWhile pioneering in TIL technology, the business remains early in its commercial lifecycle with scaling hurdles.
Dividend incomeLow / noneNo dividend is paid, making the stock entirely unsuitable for income-focused strategies.
Execution riskHighSuccessfully scaling autologous manufacturing and expanding hospital treatment centers is critical for financial viability.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.39B USD
Price to earnings Ratio -
1Y Target Price 14.5
Price to earnings Ratio -
1Y Target Price 14.5
Volume (30-day avg) 13.7M shares
Beta 0.84
52 Weeks Range 2.08 - 15.37
Updated Date 11/20/2026
52 Weeks Range 2.08 - 15.37
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.49

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
61.0%
Active BUY / eligible
64 / 105
30-Day BUY Count Change
+16
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
44.7%
Active BUY / eligible
17 / 38
30-Day BUY Count Change
+9

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 29.32%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IOVA receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
IOVA has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+60.6%) is partially offset by negative earnings growth (-5.1%), weak cash generation (FCF margin -127.6%), weak profitability (net margin -148.4%).

Financial Health Rating

★★★★★
IOVA's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 33.3%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is IOVA's strongest growth driver at +60.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-5.1%, negative) and free-cash-flow growth (+7.6%, moderate) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 67.3% and approximately 87.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.35%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 7.99%
Mhr Fund Management Llc 6.26%
State Street Corp 5.29%
Two Sigma Investments LLC 4.11%
Vanguard Capital Management, LLC 3.93%

Unit Economics (Per $1K Revenue)

★★★★★
IOVA generates approximately $343 of gross profit, $-1,511 of operating income, and $-1,276 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.53%

Quantitative Style Profile

★★★★★
IOVA has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product Revenue (Amtagvi)Commercial sales of Amtagvi for advanced melanoma following authorized treatment center administration.The primary engine of future financial growth relies on doctors prescribing and hospitals successfully administering Amtagvi.
Product Revenue (Proleukin)Global sales of Proleukin to third parties and for use alongside clinical and commercial TIL treatments.Provides a secondary, established revenue stream while securing an essential supply component for the core therapy.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3.05B
Price to Sales(TTM) 8.94
Enterprise Value 3.05B
Price to Sales(TTM) 8.94
Enterprise Value to Revenue 8.26
Enterprise Value to EBITDA -8.68
Shares Outstanding 462.66M
Shares Floating 403.97M
Shares Outstanding 462.66M
Shares Floating 403.97M
Percent Insiders 0.35
Percent Institutions 67.34

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.